Investigation of the Effect of Remimazolam on Circulatory Management in Transurethral Resection of Bladder Tumor with 5-Aminolevulinic Acid

Investigation of the Effect of Remimazolam Use on Circulatory Management in Transurethral Resection of Bladder Tumor with 5-Aminolevulinic Acid - Investigation of the Effect of Remimazolam on Circulatory Management in Transurethral Resection of Bladder Tumor

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052910

Enrollment

200

Registered

2023-11-27

Start date

2023-12-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle layer non-invasive bladder cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: PDD-TUR-Bt cases managed with sevoflurane and remimazolam among surgeries performed between April 2019 and March 2024

Exclusion criteria

Exclusion criteria: 1) TUR-Bt patients who used anesthesia maintenance drugs other than sevoflurane and remimazolam 2) TUR-Bt patients who did not use PDD 3) Patients who expressed their refusal to participate in this study through the information disclosure document 4) Other cases deemed inappropriate by the investigator.

Design outcomes

Primary

Measure	Time frame
Intraoperative minimum mean blood pressure value and duration	—

Secondary

Measure	Time frame
Circulatory Agonist Usage	—

Countries

Japan

Contacts

Public ContactKatsuhiko Ishibashi

Chiba University Hospital Anesthesiology

katsu1484@chiba-u.jp043-222-7171

Outcome results